Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 34

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 34
---
 Capital Market under the symbol “INKT.” On December 9, 2025, the last reported sale price of the common stock on the Nasdaq Capital Market was $12.99 per share. You are urged to obtain current market quotations for our common stock. Shares of our common stock covered by this prospectus supplement and the accompanying prospectus may be sold by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”). When it receives a sale order from us, the Sales Agent has agreed to use its commercially reasonable efforts to execute on the order on mutually agreed terms. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The compensation payable to the Sales Agent for sales of common stock sold pursuant to the ATM Sales Agreement will be an aggregate of 3.0% of the gross proceeds of the sales price of common stock sold. We anticipate no other commissions or material expenses for sales under the ATM Sales Agreement. The orders will be executed at price limits imposed by us. Even though this prospectus supplement does not relate to a marketed offering of our common stock, in connection with the sale of common stock under the ATM Sales Agreement, the Sales Agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have agreed to indemnify the Sales Agent against certain civil liabilities, including liabilities under the Securities Act. See the section titled “Plan of Distribution” on page S-9of this prospectus supplement. You should read carefully and consider the “ Risk Factors” referenced on page S-5of this prospectus supplement and the risk factors described in other documents incorporated by reference herein. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Sole Sales Agent

| B. RILEY SECURITIES |

The date of this prospectus supplement is , 2025.

TABLE OF CONTENTS PROSPECTUS SUPPLEMENT

| ABOUT THIS PROSPECTUS SUPPLEMENT                      |     | S-ii |
| PROSPECTUS SUPPLEMENT SUMMARY                         |     | S-1  |
| THE OFFERING                                          |     | S-3  |
| RISK FACTORS